GlassScriptPhysician profile
Swoboda E Fox
NPI 1053543769
$5,334.29
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $1,995 · 2021: $1,648 · 2022: $314 · 2023: $168 · 2024: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $276.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $559.12 | 2019-2022 | |
| Glaxosmithkline, LLC. | $542.38 | 2019-2022 | |
| Abbott Laboratories | $527.85 | 2020-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $352.73 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $310.16 | 2019-2021 | |
| Amgen INC. | $303.72 | 2019-2022 | |
| Horizon Therapeutics Plc | $292.21 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $260.80 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.46 | 2019-2022 | |
| Abbvie INC. | $198.22 | 2020-2023 | |
| Radius Health, INC. | $194.03 | 2019-2021 | |
| Amarin Pharma, INC. | $167.77 | 2019-2021 | |
| Pfizer INC. | $152.39 | 2019-2021 | |
| Astellas Pharma US INC | $144.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $141.23 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $114.44 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $107.80 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.92 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $83.26 | 2019-2021 | |
| Nabriva Therapeutics, Plc | $77.37 | 2020 | |
| Sanofi-Aventis U.S. LLC | $75.90 | 2019-2020 | |
| Redhill Biopharma INC. | $46.71 | 2020 | |
| Sunovion Pharmaceuticals INC. | $44.81 | 2019 | |
| Vanda Pharmaceuticals INC. | $41.43 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $41.35 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $39.06 | 2020-2021 | |
| Mylan Specialty L.P. | $34.98 | 2019 | |
| Hikma Pharmaceuticals USA | $25.03 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $24.03 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.99 | 2022 | |
| Phadia US INC. | $18.91 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.69 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.75 | 2020 | |
| Allergan, INC. | $15.27 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.40 | 2021 | |
| Scilex Pharmaceuticals INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swoboda Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.